Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $145

Benzinga · 1d ago
Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price target from $155 to $145.